11月3日——奇耶斯全球罕见疾病公司请求欧洲药品管理局（EMA）药物评审委员会（CHMP）对其提出的每四周给药2 mg/kg的Elfabrio方案的负面意见进行重新审查。奇耶斯全球罕见疾病公司和Protalix BioTherapeutics正在向EMA申请重新审查Elfabrio（Pegunigalsidase Alfa）在欧盟的替代给药方案的负面意见。目前Elfabrio的现有市场授权仍然有效。
11月3日——奇耶斯全球罕见疾病公司请求欧洲药品管理局（EMA）药物评审委员会（CHMP）对其提出的每四周给药2 mg/kg的Elfabrio方案的负面意见进行重新审查。奇耶斯全球罕见疾病公司和Protalix BioTherapeutics正在向EMA申请重新审查Elfabrio（Pegunigalsidase Alfa）在欧盟的替代给药方案的负面意见。目前Elfabrio的现有市场授权仍然有效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.